GSK’s Breo Ellipta Marches Forward For Asthma, Efficacy Undistinguished From Advair
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Follow-on may continue to face adoption challenges with expanded indication despite dosing convenience.